As bankers predict a rise in private equity exits this year, one of 2024’s M&A moves could come from the drug manufacturing realm.
Investment giant Bain Capital is weighing a potential sale of its Dutch antibiotics and active pharmaceutical ingredients (API) specialist Centrient Pharmaceuticals, which could be valued as high as €1 billion ($1.09 billion), Bloomberg reported Wednesday, citing people close to the talks.
To work through the potential sell-off, Bain has enlisted Citigroup and Jefferies Financial Group, the news outlet reports. The talks are ongoing and don’t guarantee that a sale will manifest, Bloomberg’s sources said.
Previously known as DSM Sinochem Pharmaceuticals, Centrient was bought out by Bain and adopted its new name in late 2018.
The company traces its roots back all the way to 1869, according to Centrient’s website. These days, Centrient boasts around 1,800 employees with operations on four continents. The company specifically focuses on enzymatic antibiotics, next generation statins and anti-fungals. Centrient also produces and sells intermediates and APIs, plus tablets, capsules and other finished dosage forms.
Regarding the CDMO’s manufacturing footprint, Centrient says it operates six production facilities across The Netherlands, Spain, India, Mexico and China.
Like most drug manufacturers, Centrient hasn’t always stayed on the U.S. FDA’s good side. In late 2022, the company was slapped with a warning letter at its manufacturing facility in the Indian state of Punjab for lapses in its drug ingredients production processes.
By Fraiser Kansteiner
Source: fiercepharma.com
SGD Pharma collaborates with Prince Sterilization Services to introduce My Sterinity Nasal vials for North America. The RTU Type I glass vials cater to the growing nasal drug delivery market, offering enhanced purity and sterility assurance. Produced at SGD Pharma’s Saint-Quentin-La-Motte facility, the vials ensure quality and supply chain reliability for US biopharma customers.
Johnson & Johnson’s (J&J) blockbuster cancer immunotherapy, Darzalex (daratumumab), has secured European approval for self-administration, marking the first time an oncology injectable has achieved this milestone on the continent.
UCB announced last week that it has selected Gwinnett County, Georgia as the location for its new U.S. biologics manufacturing facility. The campus will be state-of-the art, using a digital-first approach by leveraging AI, robotics, and automation while being natural resources efficient.
